GEN Exclusives

More »

GEN News Highlights

Back to Item »

Intercept Signs Potentially $163M Diabetes Drug Development Deal with Servier

Firms will exploit Intercept’s bile acids expertise to develop agonists of TGR5 for treating type 2 diabetes and related metabolic conditions.

Forward this item to a colleague:


 
   

(Separate multiple addresses by commas)

   

(Separate multiple addresses by commas)

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Biosimilars

Compared to the original biologics, do you think biosimilars run the risks of being less effective and causing more side effects?